Noelia Jara-Rico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noelia Jara-Rico has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Matijasevich
Departamento de Medicina Preventiva, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brasil
1 shared publication - Elena Boluda-Verdú
Department of Clinical Medicine, Miguel Hernández University, Carretera Alicante-Valencia N-332, 03550 Sant Joan d’Alacant, Spain
1 shared publication - Eusebi Chiner
Pneumology Department, San Juan de Alicante University Hospital, 03550 Alicante, Spain
1 shared publication - Francisca Sivera
Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain; Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain
1 shared publication - Isabel Betlloch-Mas
Hospital General Universitario de Alicante, España
1 shared publication - José Carlos Pascual
Department of Dermatology Hospital General Universitario Dr. Balmis, ISABIAL Alicante Spain
1 shared publication
Latest Publications
- Open Access
Scabies in Infants: Series of 51 Cases
We conducted a two-year retrospective evaluation of infants aged under two years with a confirmed, clinical, or suspected diagnosis of scabies in a healthcare center in Alicante (Spain) to determine possible factors associated with diagnostic delay and poor treatment response. We collected epidemiological, clinical, diagnostic, and treatment variables. After describing our findings as mean values and percentages, we compared categorical variables using the Student’s t-test and the Mann–Whitney U test, and we compared continuous variables with the Chi2 test and Pearson’s correlation coefficient. We included 51 infants (19 boys and 32 girls) with a mean age of 15 months. The main source of contagion was the family; half of the infants lived with four or more people. According to the International Consensus Criteria for the Diagnosis of Scabies, confirmed scabies was diagnosed in 45% of cases and clinical scabies in 47%, and 45% of cases had a diagnostic delay. Lesions mainly affected the hands, feet, and trunk, with papules in 92% of cases and burrows in 55%. The predominant symptoms were pruritus (94%) and irritability (69%). Regarding treatment, 98% of the infants received topical permethrin and 35% received oral ivermectin. Treatment failed in 76% of infants. Living in large family units was associated with a higher risk of contagion and therapeutic failure. Diagnostic delay was associated with previous misdiagnosis.
Open AccessScabies in Infants: Series of 51 Cases
We conducted a two-year retrospective evaluation of infants aged under two years with a confirmed, clinical, or suspected diagnosis of scabies in a healthcare center in Alicante (Spain) to determine possible factors associated with diagnostic delay and poor treatment response. We collected epidemiological, clinical, diagnostic, and treatment variables. After describing our findings as mean values and percentages, we compared categorical variables using the Student’s t-test and the Mann–Whitney U test, and we compared continuous variables with the Chi2 test and Pearson’s correlation coefficient. We included 51 infants (19 boys and 32 girls) with a mean age of 15 months. The main source of contagion was the family; half of the infants lived with four or more people. According to the International Consensus Criteria for the Diagnosis of Scabies, confirmed scabies was diagnosed in 45% of cases and clinical scabies in 47%, and 45% of cases had a diagnostic delay. Lesions mainly affected the hands, feet, and trunk, with papules in 92% of cases and burrows in 55%. The predominant symptoms were pruritus (94%) and irritability (69%). Regarding treatment, 98% of the infants received topical permethrin and 35% received oral ivermectin. Treatment failed in 76% of infants. Living in large family units was associated with a higher risk of contagion and therapeutic failure. Diagnostic delay was associated with previous misdiagnosis.
- 26 September 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (1) , 125-127
Drug survival of metformin in patients with hidradenitis suppurativa
Despite there being published studies on the survival of oral retinoids and biological drugs in people with hidradenitis suppurativa (HS), there is little scientific evidence on the use of metformin in this setting. We conducted a single-centre, retrospective cohort study in Spain, between January 2015 and December 2021 to determine the drug survival of metformin at 12 months in people with HS in a real-world setting. We concluded that drug survival of metformin is relatively long: half the patients were still on the drug after 1 year of treatment and one in five patients were still on the drug after 2 years.
- 26 September 2023
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (1) , 125-127
Drug survival of metformin in patients with hidradenitis suppurativa
Despite there being published studies on the survival of oral retinoids and biological drugs in people with hidradenitis suppurativa (HS), there is little scientific evidence on the use of metformin in this setting. We conducted a single-centre, retrospective cohort study in Spain, between January 2015 and December 2021 to determine the drug survival of metformin at 12 months in people with HS in a real-world setting. We concluded that drug survival of metformin is relatively long: half the patients were still on the drug after 1 year of treatment and one in five patients were still on the drug after 2 years.